Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
1
Historical Events
1
Regulatory Approvals
1 competitor in Glycogen Storage Disease Type II
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Nexviadyme
Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid ?-glucosidase deficiency).
View on EMAInfluenza (Healthy Volunteers)
Type 2 Diabetes Mellitus
Diphtheria
Non Small Cell Lung Cancer
Influenza